Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication ANORO ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use ANORO ELLIPTA is NOT indicated for the relief of acute bronchospasm or for the treatment of asthma. The safety and effectiveness of ANORO ELLIPTA in asthma have not been established. FDA label
Also known as Anoro ELLIPTA
LAMA/LABA · 1 trial · 1 indication
Intensity of dyspnea (defined as breathing discomfort) at a standardized time (isotime) during constant work rate exercise tests as measured by the modified 10-point Borg scale. A rating of 0 represents no dyspnea up to a maximum of 10: a smaller rating is therefore an improvement. Isotime was defined as the highest exercise time in minutes completed in both post-treatment tests.
| Arm | Type | Description |
|---|---|---|
| LAMA alone, then LAMA/LABA combination | EXPERIMENTAL | Participants will first receive an inhaled long-acting muscarinic antagonist (LAMA) once daily for 4 weeks. After a 2 week washout period, they will then receive the fixed-dose combination product \[LAMA plus long-acting beta2-agonist (LABA)\] once daily for 4 weeks. |
| LABA/LAMA combination, then LAMA alone | EXPERIMENTAL | Participants will first receive a long-acting muscarinic antagonist (LAMA) plus long-acting beta2-agonist (LABA) combination product once daily for 4 weeks. After a 2 week washout period, they will then receive the LAMA single product once daily for 4 weeks. |
| Name | Type | Description |
|---|---|---|
| LAMA/LABA | DRUG | GSK573719/GW642444 inhalation powder used in the Novel Dry Powder Inhaler (DPI): a long-acting beta2-agonist (GSK642444, 25mcg) with a long-acting muscarinic antagonist (GSK573719, 125mcg) combination therapy will be taken once daily for 4 weeks. |
| LAMA | DRUG | GSK573719 (125mcg) inhalation powder is a long-acting muscarinic antagonist that will be taken once daily for 4 weeks |
Inclusion Criteria: * Stable moderate COPD * Post-bronchodilator FEV1/FVC\<0.7 and 50%≤FEV1\<80% predicted * Baseline Dyspnea Index ≤ 9 and MRC dyspnea scale \>2 * Cigarette smoking history at least 20 pack-years Exclusion Criteria: * Presence of a significant disease other than COPD that could c...
Top 11 of 14 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 8 | PHASE3 | Depemokimab, GSK5784283, GSK3862995B |
| AstraZeneca PLC | AZN | 14 | PHASE3 | Tezepelumab, Breztri, Bevespi, Tozorakimab, AZD6793 |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Lunsekimig, SAR447537, Dupilumab |
| Merck & Co., Inc. | MRK | 3 | PHASE3 | Ensifentrine, Frespaciguat |
| Pfizer Inc. | PFE | 2 | PHASE3 | tilrekimig and rHuPH20, PF-07275315 |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Alpha-1 MP |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Astegolimab, RO7830698 |
| Generate Biomedicines, Inc. | GENB | 1 | PHASE1 | GB-0895 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | Tyvaso (treprostinil) |